Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957859 | 0.87 | ADRB2 (0.44) | ADRB2PDE2ATRPV3GLSFFAR4 | |
| SCHEMBL22957678 | 0.83 | ADRB2 (0.49) | ADRB2GLSSLC6A4 | |
| SCHEMBL15979346 | 0.83 | MTNR1B (0.46) | ADRB2 | |
| SCHEMBL5768808 | 0.82 | TACR1 (0.50) | SLC6A3TACR1 | |
| SCHEMBL21216304 | 0.80 | ADRB2 (0.53) | ADRB2PDE2AGLSFFAR4MPO | |
| SCHEMBL22624065 | 0.80 | ADRB2 (0.47) | ADRB2GLSFFAR4MPOGPR3 | |
| SCHEMBL24018765 | 0.80 | ADRB2 (0.46) | ADRB2GLSFFAR4MPOGPR3 | |
| SCHEMBL17449711 | 0.80 | PDE2A (0.44) | ADRB2PDE2ASLC6A4SLC6A3FFAR4 | |
| SCHEMBL15599254 | 0.77 | PDE2A (0.44) | ADRB2PDE2AFFAR4MPOGPR3 | |
| SCHEMBL10978751 | 0.77 | GPR3 (0.42) | ADRB2PDE2AFFAR4MPODPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ADRB2 3001/4885PDE2A 1905/4885TRPV3 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.